Evaluation of Outcomes following Radiofrequency Ablation for Treatment of Parotid Tail Warthin Tumors

Tung, Yu-Cheng; Luo, Sheng‐Dean; Su, Yan-Ye; Chen, Wei-Chih; Chen, Hsiu-Ling; Cheng, Kai-Lun; Lin, Wei-Che

doi:10.1016/j.jvir.2019.04.031

Cited by 13 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we updated our previous study of the use of RFA to treat Warthin tumors. Our previous study was of seven patients who were not divided into cystic versus solid groups [ 14 ]. In that study, we only followed volume reduction and cosmetic change in patients for six months.…”

Section: Discussionmentioning

confidence: 99%

“…Tumor size, wound condition, cosmetic scale and patient satisfaction were assessed in each patient postoperatively at week one, month one and month six, at least. At enrollment, each patient’s tumor was assigned a cosmetic score: 1 being a non-palpable mass; 2 being an invisible but palpable mass; 3 being a parotid tumor that bulged when teeth were gritted; 4 being a clearly visible mass [ 14 ]. Complications were categorized as perioperative (within 1 week), early (after 1 week and within 6 months), or delayed (after 6 months), graded according to The Clavien-Dindo Classification.…”

Section: Methodsmentioning

confidence: 99%

“…Previously, we used radiofrequency ablation (RFA) to treat seven Warthin tumors [ 14 ]. We found that the ultrasound-guided RFA moving shot technique was a safe and effective alternative treatment for parotid tail Warthin tumors in the seven patients for whom surgical resection was contraindicated, or for those were unwilling to receive surgical resection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long-Term Outcomes of Radiofrequency Ablation for Treatment of Cystic Warthin Tumors versus Solid Warthin Tumors

Cha

Luo

Chiang

et al. 2021

IJERPH

Self Cite

View full text Add to dashboard Cite

Background: To describe the long-term outcomes of radiofrequency ablation (RFA) of parotid Warthin tumors that have different consistencies and locations. Methods: We reviewed ten patients with Warthin tumors undergoing RFA treatment from 2016 to 2019. The mean follow-up was 24.3 ± 13.1 months (range 7–42 months). Results: RFA was performed on 11 tumors in ten patients. Cystic tumors (n = 4) had better volume reduction ratios (VRR) than solid tumors (n = 7) at month one and month six, following RFA (77.9% vs. 47.3%, 95.1% vs. 80.6%, respectively, p = 0.003). Tumors in both superficial lobes and deep lobes (n = 7) were larger than tumors in superficial lobes alone (n = 4), though there was no difference in VRR after treatment. All residual tumors were found in superficial lobes. There was no increase in residual tumor size. Every patient showed marked cosmetic improvements, with visible tumors becoming non-palpable masses. Conclusions: RFA is a safe and effective treatment for Warthin tumors, with better volume reduction in cystic tumors. Results remained satisfying over the long-term for all residual tumors found in superficial lobes, making it easier for re-intervention if necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-Term Outcomes of Radiofrequency Ablation for Treatment of Cystic Warthin Tumors versus Solid Warthin Tumors

Cha

Luo

Chiang

et al. 2021

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Experience with non-surgical options in the management of WTs is limited. Three recent studies described three potential new approaches: microwave ablation (MWA) [48], radiofrequency (RF) [49], and ultrasound-guided ethanol sclerotherapy (UGES) [50]. The first two options have a long history in the treatment of other neoplasms, especially liver tumors, with a therapeutic effect based on thermal injury.…”

Section: Alternatives To Surgery and Asmentioning

confidence: 99%

Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland

et al. 2021

View full text Add to dashboard Cite

Purpose: To review the current options in the management of Warthin tumors (WTs) and to propose a working management protocol. Methods: A systematic literature search was conducted using PubMed and ScienceDirect database. A total of 141 publications were selected and have been included in this review. Publications were selected based on relevance, scientific evidence, and actuality. Results: The importance of parotid WTs is increasing due to its rising incidence in many countries, becoming the most frequently encountered benign parotid tumor in certain parts of the world. In the past, all WTs were treated with surgery, but because of their slow growth rate, often minimal clinical symptoms, and the advanced age of many patients, active observation has gradually become more widely used. In order to decide on active surveillance, the diagnosis of WT must be reliable, and clinical, imaging, and cytological data should be concordant. There are four clear indications for upfront surgery: uncertain diagnosis; cosmetic problems; clinical complaints, such as pain, ulceration, or recurrent infection; and the patient’s wish to have the tumor removed. In the remaining cases, surgery can be elective. Active surveillance is often suggested as the first approach, with surgery being considered if the tumor progresses and/or causes clinical complaints. The extent of surgery is another controversial topic, and the current trend is to minimize the resection using partial parotidectomies and extracapsular dissections when possible. Recently, non-surgical options such as microwave ablation, radiofrequency ablation, and ultrasound-guided ethanol sclerotherapy have been proposed for selected cases. Conclusions: The management of WT is gradually shifting from superficial or total parotidectomy to more conservative approaches, with more limited resections, and to active surveillance in an increasing number of patients. Additionally, non-surgical treatments are emerging, but their role needs to be defined in future studies.

show abstract

“…Ultrasound-guided radiofrequency ablation (RFA) is a minimally invasive procedure for use on benign and malignant tumors, including hepatocellular carcinoma, hepatic metastatic tumor, thyroid nodules, parathyroid adenoma, musculoskeletal soft tissue tumors, and parotid Warthin tumors [ 11 , 12 , 13 , 14 , 15 , 16 ]. In contrast to the conventional fixed electrode technique during ablation, RFA using the moving-shot technique facilitates real-time monitoring of the procedure, making it possible to perform RFA in more delicate locations and to avoid vital structure damage [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Ultrasound-Guided Moving Shot Radiofrequency Ablation of Benign Soft Tissue Neoplasm

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background and Objective: To evaluate the effectiveness of radiofrequency ablation (RFA) using the moving-shot technique for benign soft tissue neoplasm. Materials and Methods: This retrospective study reviewed eight patients with benign soft tissue neoplasm presenting with cosmetic concerns and/or symptomatic issues who refused surgery. Six patients had vascular malformation, including four with venous malformation and two with congenital hemangioma. The other two patients had neurofibroma. All patients underwent RFA using the moving-shot technique. Imaging and clinical follow-up were performed in all patients. Follow-up image modalities included ultrasound (US), computed tomography (CT), and magnetic resonance (MR) imaging. The volume reduction ratio (VRR), cosmetic scale (CS), and complications were evaluated. Results: Among the seven patients having received single-stage RFA, there were significant volume reductions between baseline (33.3 ± 21.2 cm3), midterm follow-up (5.1 ± 3.8 cm3, p = 0.020), and final follow-up (3.6 ± 1.4 cm3, p = 0.022) volumes. The VRR was 84.5 ± 9.2% at final follow-up. There were also significant improvements in the CS (from 3.71 to 1.57, p = 0.017). The remaining patient, in the process of a scheduled two-stage RFA, had a 33.8% VRR after the first RFA. The overall VRR among the eight patients was 77.5%. No complications or re-growth of the targeted lesions were noted during the follow-up period. Of the eight patients, two received RFA under local anesthesia, while the other six patients were under general anesthesia. Conclusions: RFA using the moving-shot technique is an effective, safe, and minimally invasive treatment for benign soft tissue neoplasms, achieving mass volume reduction within 6 months and significant esthetic improvement, either with local anesthesia or with general anesthesia under certain conditions.

show abstract

Evaluation of Outcomes following Radiofrequency Ablation for Treatment of Parotid Tail Warthin Tumors

Cited by 13 publications

References 14 publications

Long-Term Outcomes of Radiofrequency Ablation for Treatment of Cystic Warthin Tumors versus Solid Warthin Tumors

Long-Term Outcomes of Radiofrequency Ablation for Treatment of Cystic Warthin Tumors versus Solid Warthin Tumors

Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland

Ultrasound-Guided Moving Shot Radiofrequency Ablation of Benign Soft Tissue Neoplasm

Contact Info

Product

Resources

About